Arthur Kuan, CG Oncology CEO

#AS­CO2022 roundup: CG On­col­o­gy builds on head-turn­ing com­bo da­ta; EQRx doesn’t have a way in­to US mar­kets

CG On­col­o­gy at­tract­ed some at­ten­tion last month at #AACR22 for its ear­ly da­ta on its on­colyt­ic virus paired with Mer­ck’s Keytru­da for blad­der can­cer, and up­dat­ed num­bers from AS­CO don’t dis­ap­point.

In a Phase II study, 22 out of 24 pa­tients have had a com­plete re­sponse to the com­bo treat­ment at an ear­ly 3-month check-in, good for a 92% ini­tial re­sponse rate. At 6 months, that drops to 14 of 16, and at one year — the pri­ma­ry end­point of the study — 6 of 8 pa­tients main­tained a com­plete re­sponse.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.